Core Insights - Skye Bioscience, Inc. presented results from a Phase 1b study of nimacimab for metabolic-associated steatotic liver disease (MASLD) at the EASD Annual Meeting, highlighting its safety and tolerability profile [1][2][3] Company Overview - Skye Bioscience is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][5] - The company aims to create first-in-class therapeutics by leveraging biologic targets with substantial human proof of mechanism [5] Study Results - The Phase 1b study demonstrated that nimacimab was safe and well-tolerated, with no serious adverse events or discontinuations due to adverse events [2][3] - Gastrointestinal side effects were infrequent and mild, indicating a differentiated tolerability profile for nimacimab [2] - The study was previously conducted by Bird Rock Bio, Inc., which was acquired by Skye in 2023 [3] Future Focus - Skye's immediate focus is on the upcoming topline readout from the CBeyond™ Phase 2a obesity study, which is assessing nimacimab's efficacy [3][5] - The Phase 2a clinical trial is also evaluating the combination of nimacimab with a GLP-1R agonist (Wegovy®) [5]